Filana Therapeutics: Pay

Filana Therapeutics paid its 3 named executives $3.2M in total in FY2025 (Dec). CEO Richard J. Barry was paid $1.5M of that.

Pay$100 in the stock at the end of FY22 → $7
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Richard J. BarryPresident and Chief Executive Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
3 years
Eric J. SchoenChief Financial Officer
FY2025 (Dec)Not disclosed
FY2024 (Dec)Not disclosed
FY2023 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
5 years
R. Christopher CookChief Operating and Legal Officer
FY2025 (Dec)Not disclosed
FY2024 (Dec)Not disclosed
FY2023 (Dec)
FY2022 (Dec)Not disclosed
4 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 10 peers with pay on file was $3.5M. The CEO of Filana Therapeutics was paid $1.5M, 56% below the median.

  1. 1Inhibikase Therapeutics
  2. 2Avalo Therapeutics
  3. 3Corbus Pharmaceuticals Holdings
  4. 4Annexon
  5. 5Larimar Therapeutics
  6. 6Atea Pharmaceuticals
  7. 7Eledon Pharmaceuticals
  8. 8Protara Therapeutics
  9. 9Inmune Bio
  10. 10Filana Therapeutics
  11. 11Skye Bioscience
  12. 12Atossa TherapeuticsNot disclosed
  13. 13Cardiff OncologyNot disclosed
  14. 14Climb Bio, Inc.Not disclosed
  15. 15Coya TherapeuticsNot disclosed
  16. 16Jasper TherapeuticsNot disclosed
  17. 17MedicinovaNot disclosed
  18. 18Quince Therapeutics, Inc.Not disclosed
  19. 19Sagimet BiosciencesNot disclosed
  20. 20Zura BioNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.